Devices & Diagnostics

HealthTell’s marketing language jabs at Theranos (also, it’s raising $5M for its own single-drop-of-blood diagnostics)

Examining the immune system’s response to disease has been a hot new area in diagnostics – particularly when done with a single drop of blood, as has been widely publicized with the ever-evasive Theranos. Arizona startup HealthTell studies the immunosignatures found in small samples of blood to suss out whether a patient has certain cancers, autoimmune and […]

Examining the immune system’s response to disease has been a hot new area in diagnostics – particularly when done with a single drop of blood, as has been widely publicized with the ever-evasive Theranos. Arizona startup HealthTell studies the immunosignatures found in small samples of blood to suss out whether a patient has certain cancers, autoimmune and infectious disease.

While Theranos’ methodology is cloaked in secrecy, HealthTell is making it a point to emphasize its transparency.

The company has been likened to Theranos before, in that the two are “out for blood” – using small blood samples to scope out a litany of disease. Except that while Theranos conducts your basic labs, HealthTell is after early diagnosis of cancers, Alzheimer’s and autoimmune disease.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

HealthTell’s language is pretty amusing: “HealthTell takes pride in being a transparent, data driven company passionate about sharing our diagnostic technology with the world.” Generally the opposite approach of Theranos, no? It’s also curious that HealthTell, as with Theranos, touts the ability to profile more than 30 diseases. While their disease targets are vastly different, there’s definitely an undercurrent of competition going on.

The Arizona State University spinout has previously said that it means to commercialize its diagnostics this year, and is in the midst of a new $5 million round, according to a regulatory filing. It’s thus far raised about $4 million, the filing says. Prior to this round, it’s raised nearly $17 million since 2013.

HealthTell recently expanded its offerings to rapidly diagnose infections and autoimmune diseases like Valley Fever and lupus.